GlassScriptPhysician profile
Babak Ghadishah
NPI 1346272408
$6,203.82
in general payments reported to CMS, 2019-2025
44 companies · $1,117 in 2025
The $1,117 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $404 · 2021: $678 · 2022: $1,129 · 2023: $1,217 · 2024: $1,310 · 2025: $1,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,446 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,446.20 |
| Education | $197.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $763.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $711.52 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $630.94 | 2019-2025 | |
| Abbvie INC. | $612.64 | 2020-2025 | |
| Glaxosmithkline, LLC. | $595.41 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $329.73 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $229.37 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
| Edwards Lifesciences Corporation | $215.53 | 2022-2025 | Sapien 3 Ultra Resilia |
| Amgen INC. | $205.69 | 2022-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $205.18 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $199.61 | 2020-2022 | |
| Abbott Laboratories | $179.57 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $160.15 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.22 | 2021-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $106.34 | 2020-2021 |
Show all 43 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Babak Ghadishah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.